Literature DB >> 17487362

Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo.

Tadeusz Issat1, Dominika Nowis, Magdalena Legat, Marcin Makowski, Marcin P Klejman, Jakub Urbanski, Janusz Skierski, Miroslawa Koronkiewicz, Tomasz Stoklosa, Agnieszka Brzezinska, Jacek Bil, Jan Gietka, Marek Jakóbisiak, Jakub Golab.   

Abstract

The aim of the present study was to examine the potential antitumor activity of lovastatin and other statins together with pamidronate, a second generation bisphosphonate (BP), against tumor cell lines. Cytostatic/cytotoxic effects were measured using crystal violet assay. Regulation of the cell cycle and induction of apoptosis were evaluated using flow cytometry and Western blotting, migration of tumor cells was measured in a scratch wound assay and their invasiveness was measured with a Matrigel-invasion assay. Antitumor effects of the combination treatment were evaluated in a murine PANC 02 pancreatic adenocarcinoma model. Combination of pamidronate and lovastatin produced potentiated cytostatic/cytotoxic effects against breast and pancreatic cancer cell lines. The combination was also effective in inhibition of tumor cell adhesion to collagen IV and fibronectin and interfered with migration and invasiveness of tumor cells. Neither pamidronate nor lovastatin alone affected tumor growth in mice but the combination treatment resulted in retardation of tumor growth and prolongation of mouse survival. The combination of statins and pamidronate, a second generation bisphosphonate, demonstrates promising antitumor effects at doses readily achievable in patients. This combination holds promise for future clinical studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487362

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.

Authors:  Altaf Mohammed; Li Qian; Naveena B Janakiram; Stan Lightfoot; Vernon E Steele; Chinthalapally V Rao
Journal:  Int J Cancer       Date:  2012-03-14       Impact factor: 7.396

2.  Differential and Joint Effects of Metformin and Statins on Overall Survival of Elderly Patients with Pancreatic Adenocarcinoma: A Large Population-Based Study.

Authors:  Jian-Yu E; Shou-En Lu; Yong Lin; Judith M Graber; David Rotter; Lanjing Zhang; Gloria M Petersen; Kitaw Demissie; Grace Lu-Yao; Xiang-Lin Tan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-06-15       Impact factor: 4.254

3.  A novel chemical screening strategy in zebrafish identifies common pathways in embryogenesis and rhabdomyosarcoma development.

Authors:  Xiuning Le; Emily K Pugach; Simone Hettmer; Narie Y Storer; Jianing Liu; Airon A Wills; Antony DiBiase; Eleanor Y Chen; Myron S Ignatius; Kenneth D Poss; Amy J Wagers; David M Langenau; Leonard I Zon
Journal:  Development       Date:  2013-04-24       Impact factor: 6.868

4.  Statins and pancreatic cancer.

Authors:  Jun Gong; Esha Sachdev; Lori A Robbins; Emily Lin; Andrew E Hendifar; Monica M Mita
Journal:  Oncol Lett       Date:  2017-01-04       Impact factor: 2.967

5.  Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.

Authors:  Adam R Wolfe; Bisrat G Debeb; Lara Lacerda; Richard Larson; Arvind Bambhroliya; Xuelin Huang; Francois Bertucci; Pascal Finetti; Daniel Birnbaum; Steven Van Laere; Parmeswaran Diagaradjan; Brian Ruffell; Nicholaus J Trenton; Khoi Chu; Walter Hittelman; Michael Diehl; Ilya Levental; Naoto T Ueno; Wendy A Woodward
Journal:  Breast Cancer Res Treat       Date:  2015-11-21       Impact factor: 4.872

6.  Inhibition of growth and migration of cholangiocarcinoma cells by pamidronate.

Authors:  Benjaporn Buranrat; Auemduan Prawan; Laddawan Senggunprai; Veerapol Kukongviriyapan
Journal:  Exp Ther Med       Date:  2019-09-23       Impact factor: 2.447

7.  Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice.

Authors:  Dominika Nowis; Marek Bugajski; Magdalena Winiarska; Jacek Bil; Angelika Szokalska; Pawel Salwa; Tadeusz Issat; Halina Was; Alicja Jozkowicz; Jozef Dulak; Tomasz Stoklosa; Jakub Golab
Journal:  BMC Cancer       Date:  2008-07-11       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.